Study of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approaches

Abstract Methotrexate-encapsulated solid lipid nanoparticles (MTX-SLNs) and lactoferrin-decorated MTX-loaded nanoparticles (MTX-Lf-SLNs) present a promising strategy for treating colorectal cancer. Among different molecular targets, MTX demonstrated the highest affinity for Caspase-6, exhibiting a d...

Full description

Saved in:
Bibliographic Details
Main Authors: Sankha Bhattacharya, Ranajit Nivrutti Shinde, Vishal Beldar, Rehan Khan
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-08089-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849400034252029952
author Sankha Bhattacharya
Ranajit Nivrutti Shinde
Vishal Beldar
Rehan Khan
author_facet Sankha Bhattacharya
Ranajit Nivrutti Shinde
Vishal Beldar
Rehan Khan
author_sort Sankha Bhattacharya
collection DOAJ
description Abstract Methotrexate-encapsulated solid lipid nanoparticles (MTX-SLNs) and lactoferrin-decorated MTX-loaded nanoparticles (MTX-Lf-SLNs) present a promising strategy for treating colorectal cancer. Among different molecular targets, MTX demonstrated the highest affinity for Caspase-6, exhibiting a docking score of -9.316, while molecular dynamics validated stable interactions. The optimized nanoparticles displayed a spherical shape (~ 160 nm, as observed in TEM images) with a high drug encapsulation efficiency of 85.87% for MTX-SLNs and 80.11% for MTX-Lf-SLNs, which ensured improved stability. Structural analyses using FTIR, DSC confirmed effective drug encapsulation and the binding of lactoferrin. Interestingly, MTX-Lf-SLNs demonstrated higher cytotoxicity (IC50: 0.51 µM) compared to MTX-SLNs and free MTX, inducing apoptosis and stopping cell cycle progression in HCT116 cells. This improved effect was associated with receptor-driven absorption through lactoferrin targeting. Nanoparticulate formulations decreased TNF-α (17.6 ± 2.1 pg/mL), IL-6 (20.2 ± 1.9 pg/mL), and IL-1β (15.4 ± 3.4 pg/mL), thereby reducing immune activation. The nanoparticles exhibited extended, pH-sensitive drug release (70% at pH 5.7) and significant anti-angiogenic effects (~ 70% inhibition in CAM assay). Moreover, they enhanced the balance of reactive oxygen species and safeguarded mitochondria, thereby lowering overall toxicity. Migration assays further validated their capacity to obstruct cancer cell invasiveness, suggesting a potential to impede metastasis. Utilizing the bioactivity of lactoferrin for precise delivery, MTX-Lf-SLNs offer an attractive approach to enhance anti colon cancer efficacy while reducing unwanted side effects.
format Article
id doaj-art-067c76fd044b41c2a1184e6ecf55190e
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-067c76fd044b41c2a1184e6ecf55190e2025-08-20T03:38:12ZengNature PortfolioScientific Reports2045-23222025-07-0115112910.1038/s41598-025-08089-wStudy of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approachesSankha Bhattacharya0Ranajit Nivrutti Shinde1Vishal Beldar2Rehan Khan3School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-Be UniversitySchool of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-Be UniversitySchool of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-Be UniversityChemical Biology Unit, Institute of Nano Science and Technology (INST)Abstract Methotrexate-encapsulated solid lipid nanoparticles (MTX-SLNs) and lactoferrin-decorated MTX-loaded nanoparticles (MTX-Lf-SLNs) present a promising strategy for treating colorectal cancer. Among different molecular targets, MTX demonstrated the highest affinity for Caspase-6, exhibiting a docking score of -9.316, while molecular dynamics validated stable interactions. The optimized nanoparticles displayed a spherical shape (~ 160 nm, as observed in TEM images) with a high drug encapsulation efficiency of 85.87% for MTX-SLNs and 80.11% for MTX-Lf-SLNs, which ensured improved stability. Structural analyses using FTIR, DSC confirmed effective drug encapsulation and the binding of lactoferrin. Interestingly, MTX-Lf-SLNs demonstrated higher cytotoxicity (IC50: 0.51 µM) compared to MTX-SLNs and free MTX, inducing apoptosis and stopping cell cycle progression in HCT116 cells. This improved effect was associated with receptor-driven absorption through lactoferrin targeting. Nanoparticulate formulations decreased TNF-α (17.6 ± 2.1 pg/mL), IL-6 (20.2 ± 1.9 pg/mL), and IL-1β (15.4 ± 3.4 pg/mL), thereby reducing immune activation. The nanoparticles exhibited extended, pH-sensitive drug release (70% at pH 5.7) and significant anti-angiogenic effects (~ 70% inhibition in CAM assay). Moreover, they enhanced the balance of reactive oxygen species and safeguarded mitochondria, thereby lowering overall toxicity. Migration assays further validated their capacity to obstruct cancer cell invasiveness, suggesting a potential to impede metastasis. Utilizing the bioactivity of lactoferrin for precise delivery, MTX-Lf-SLNs offer an attractive approach to enhance anti colon cancer efficacy while reducing unwanted side effects.https://doi.org/10.1038/s41598-025-08089-wCaspase-6MethotrexateLactoferrinMolecular dockingHCT116
spellingShingle Sankha Bhattacharya
Ranajit Nivrutti Shinde
Vishal Beldar
Rehan Khan
Study of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approaches
Scientific Reports
Caspase-6
Methotrexate
Lactoferrin
Molecular docking
HCT116
title Study of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approaches
title_full Study of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approaches
title_fullStr Study of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approaches
title_full_unstemmed Study of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approaches
title_short Study of caspase-6 activity in aggressive HCT116 cells using methotrexate-encapsulated lactoferrin-conjugated solid lipid nanoparticles via in silico and in vitro approaches
title_sort study of caspase 6 activity in aggressive hct116 cells using methotrexate encapsulated lactoferrin conjugated solid lipid nanoparticles via in silico and in vitro approaches
topic Caspase-6
Methotrexate
Lactoferrin
Molecular docking
HCT116
url https://doi.org/10.1038/s41598-025-08089-w
work_keys_str_mv AT sankhabhattacharya studyofcaspase6activityinaggressivehct116cellsusingmethotrexateencapsulatedlactoferrinconjugatedsolidlipidnanoparticlesviainsilicoandinvitroapproaches
AT ranajitnivruttishinde studyofcaspase6activityinaggressivehct116cellsusingmethotrexateencapsulatedlactoferrinconjugatedsolidlipidnanoparticlesviainsilicoandinvitroapproaches
AT vishalbeldar studyofcaspase6activityinaggressivehct116cellsusingmethotrexateencapsulatedlactoferrinconjugatedsolidlipidnanoparticlesviainsilicoandinvitroapproaches
AT rehankhan studyofcaspase6activityinaggressivehct116cellsusingmethotrexateencapsulatedlactoferrinconjugatedsolidlipidnanoparticlesviainsilicoandinvitroapproaches